(22) Exploration of new anti-cancer pharmaceuticals--synthesis, characterization, and chemical biology testing
Abstract
Platinum drugs and its derivatives are being used extensively to treat cancer today. These drugs have many disadvantages including high cytotoxicity, high resistance and low cellular uptake inspiring many scientists to search... [ view full abstract ]
Platinum drugs and its derivatives are being used extensively to treat cancer today. These drugs have many disadvantages including high cytotoxicity, high resistance and low cellular uptake inspiring many scientists to search for a new metallodrug. Recently, a ruthenium metallodrug, KP1019, has entered into clinical trials and has shown promising potential including low cytotoxicity and high activity. The mode of action of KP1019 is still relatively unknown. To build on this inquiry, three new potential drugs—trans-[PtIVCl4(Ind)2], cis-[PtIVCl4(Ind)2], and cis-[PtIICl2(Ind)2]—have been made. DNA studies of cis-[PtIVCl4(Ind)2] indicate it has potential to be used as an anticancer drug. Syntheses of additional platinum derivatives with various indazole ligands have been under investigation. Initial characterization of the platinum derivatives with various indazole ligands indicate the formation of novel compounds.
Authors
-
Katharine Barwick
(The University of the South,)
-
Kendall Wills
(The University of the South,)
-
Bethel Seballos
(The University of the South, Department of Chemistry, Program in Biochemistry)
-
Robert Bachman
(The University of the South, Department of Chemistry)
Topic Area
Chemistry
Session
PS » Poster Session (14:30 - Friday, 27th April, Spencer Hall (Harris Commons))
Presentation Files
The presenter has not uploaded any presentation files.
